285984-41-0

Usage

Uses

Used in Pharmaceutical Industry:
2-(3-AMINO-PHENYL)-1-MORPHOLIN-4-YL-ETHANONE is used as an analgesic and anti-inflammatory agent for its ability to alleviate pain and reduce inflammation.
Used in Oncology:
2-(3-AMINO-PHENYL)-1-MORPHOLIN-4-YL-ETHANONE is used as an antitumor agent for its potential to inhibit the growth and progression of cancer cells.
Used in Antifungal Applications:
2-(3-AMINO-PHENYL)-1-MORPHOLIN-4-YL-ETHANONE is used as an antifungal agent for its potential to combat fungal infections.
Used in Antiviral Applications:
2-(3-AMINO-PHENYL)-1-MORPHOLIN-4-YL-ETHANONE is used as an antiviral agent for its potential to inhibit viral replication and infection.
Used in Neurological Disorders Treatment:
2-(3-AMINO-PHENYL)-1-MORPHOLIN-4-YL-ETHANONE is used as a therapeutic agent for the treatment of neurological disorders and central nervous system-related conditions due to its potential neuroprotective and neuroregenerative effects.

InChI:InChI=1/C12H16N2O2/c13-11-3-1-2-10(8-11)9-12(15)14-4-6-16-7-5-14/h1-3,8H,4-7,9,13H2

Upstream product

• 7440-44-0 pyrographite 
• 19281-20-0 4-[(3-nitro-phenyl)-acetyl]-morpholine 
• 1877-73-2 3-nitro-benzeneacetic acid 

Downstream Products

• 643086-65-1 3-(2-morpholin-4-ylethyl)-aniline 

Relevant academic research and scientific papers

AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON

The invention relates to certain aminopyrimidine compounds which inhibit TBK1 and/or IKK epsilon and which may therefore find application in treating inflammation, cancer, septic shock and/or Primary open Angle Glaucoma (POAG).

Anti-inflammatory medicaments

Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds.

MODULATION OF PROTEIN FUNCTIONALITIES

New methods for the rational identification of molecules capable of interacting with specific naturally occurring proteins are provided, in order to yield new pharmacologically important compounds and treatment modalities. Broadly, the method comprises the steps of identifying a switch control ligand forming a part of a particular protein of interest, and also identifying a complemental switch control pocket forming a part of the protein and which interacts with said switch control ligand. The ligand interacts in vivo with the pocket to regulate the conformation and biological activity of the protein such that the protein assumes a first conformation and a first biological activity upon the ligand-pocket interaction, and assumes a second, different conformation and biological activity in the absence of the ligand-pocket interaction. Next, respective samples of said protein in the first and second conformations are provided, and these are screened against one or more candidate molecules by contacting the molecules and the samples. Thereupon, small molecules which bind with the protein at the region of the pocket may be identified. Novel protein-modulator adducts and methods of altering protein activity are also provided.

Anti-inflammatory medicaments

Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds.

N-phenylamidines as selective inhibitors of human neuronal nitric oxide synthase: Structure-activity studies and demonstration of in vivo activity

Selective inhibition of the neuronal isoform of nitric oxide synthase (NOS) compared to the endothelial and inducible isoforms may be required for treatment of neurological disorders caused by excessive production of nitric oxide. Recently, we described N-(3-(aminomethyl)benzyl)acetamidine (13) as a slow, tight-binding inhibitor, highly selective for human inducible nitric oxide synthase (iNOS). Removal of a single methylene bridge between the amidine nitrogen and phenyl ring to give N-(3- (aminomethyl)phenyl)acetamidine (14) dramatically altered the selectivity to give a neuronal selective nitric oxide synthase (nNOS) inhibitor. Part of this large shift in selectivity was due to 14 being a rapidly reversible inhibitor of iNOS in contrast to the essentially irreversible inhibition of iNOS observed with 13. Structure-activity studies revealed that a basic amine functionality tethered to an aromatic ring and a sterically compact amidine are key pharmacophores for this class of NOS inhibitors. Maximal nNOS inhibition potency was achieved with N-(3-(aminomethyl)phenyl)-2- furanylamidine (77) (K(i-nNOS) = 0.006 μM; K(i-eNOS) = 0.35 μM; K(i-iNOS) = 0.16 μM). Finally, α-fluoro-N-(3-(aminomethyl)phenyl)acetamidine (74) (K(i- nNOS) = 0.011 μM; K(i-eNOS) = 1.1 μM; K(i-iNOS) = 0.48 μM) had excellent brain penetration and inhibited nNOS in a rat brain slice assay as well as in the rat brain (cerebellum) in vivo. Thus, N-phenylamidines should be useful in validating the role of nNOS in neurological disorders.